Health
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger – Business Wire
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.
…
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News22 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General13 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News17 hours agoBrisbane rising on global rankings, but still behind southern capitals